论文部分内容阅读
目的观察胺碘酮联合缬沙坦、辛伐他汀预防阵发性房颤复发的临床疗效。方法选择阵发性房颤患者81例,随机分为治疗组和对照组,治疗组口服胺碘酮、缬沙坦和辛伐他汀,对照组仅服胺碘酮,分别观察12个月后对窦性心律维持的效果、左房内经及血清C-反应蛋白(CRP)的影响。结果治疗组房颤复发率明显下降,较对照组比较,差异有统计学意义(P<0.05);治疗组左房内经显著小于对照组、血清CRP显著低于对照组(P<0.05)。结论阵发性房颤患者复律后采用胺碘酮联合缬沙坦、辛伐他汀治疗,可以有效的预防房颤复发,临床疗效优于单用胺碘酮,并能抑制左心房的扩大、减少炎症反应。
Objective To observe the clinical efficacy of amiodarone combined with valsartan and simvastatin in preventing the recurrence of paroxysmal atrial fibrillation. Methods Eighty-one patients with paroxysmal atrial fibrillation were randomly divided into treatment group and control group. The patients in treatment group were given amiodarone, valsartan and simvastatin orally. The control group was given amiodarone alone for 12 months Effect of sinus rhythm maintenance, left atrium and serum C-reactive protein (CRP). Results The recurrence rate of atrial fibrillation in the treatment group was significantly lower than that in the control group (P <0.05). The left atrium of the treatment group was significantly smaller than the control group, and the serum CRP was significantly lower than that of the control group (P <0.05). Conclusion Amiodarone combined with valsartan and simvastatin after cardioversion in patients with paroxysmal atrial fibrillation can effectively prevent the recurrence of atrial fibrillation. The clinical efficacy is superior to amiodarone alone and can inhibit the expansion of left atrium, Reduce the inflammatory reaction.